SynthesisMedicine2025
Clinical efficacy of ulinastatin in patients with pulmonary edema: A systematic review and meta-analysis of randomized controlled trials.
Synthesis in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo methodically assess the clinical impact of ulinastatin on patients suffering from pulmonary edema.
methodsPubMed, Web of Science, Cochrane Library, Embase, Chinese National Knowledge Infrastructure (CNKI), Wanfang data, Chinese Scientific Journal Database (VIP), and Chinese Biomedical Literature Database (CBM) databases were searched using such keywords as ulinastatin, pulmonary edema, and randomized controlled trial (RCT). The search time was from the establishment of the database to August 2023. Two researchers were responsible for literature screening and data collection respectively. After the risk of bias in the included studies was evaluated, meta-analysis was performed using statistical software RevMan 5.4 and GRADE profiler software was used to evaluate evidence quality.
resultsNine RCTs were included in the meta-analysis. Meta-analysis results showed that compared with conventional treatment group, the incidence of pulmonary edema of the patients in the ulinastatin group decreased, with odds ratios (OR) of 0.36 (95% CI: 0.20, 0.657), extravascular pulmonary water index (EVLWI) decreased, with mean difference (MD) of -0.75 (95% CI: -1.32, -0.17), ventilator use time decreased, with MD of -2.86 (95% CI: -0.26, 0.23), the intensive care unit (ICU) length of stay decreased, with MD of -1.56 (95% CI: -1.75, -1.38). The pulmonary vascular permeability index (PVPI) decreased in ulinastatin group, with MD of -0.10 (95% CI: -0.24, 0.03), but the difference was not statistically significant.
conclusionCompared with conventional treatment, ulinastatin may reduce the incidence of pulmonary edema, decrease EVLWI, ventilator use time and the ICU length of stay in patients with pulmonary edema, but it could not reduce PVPI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.